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The Functional and Structural Consequences of Aberrant 
Microglial Activity in Major Depressive Disorder 
Abstract 
Major depressive disorder (MDD) is a highly debilitating neuropsychiatric illness 
which has been linked with increases in both peripheral and central inflammation, as well 
as with changes in connectivity. Although countless studies have investigated these two 
topics, the relationship between neuroinflammation and functional/structural connectivity 
has not been explored. Using [18F]FEPPA PET imaging, we measured translocator 
protein-related (TSPO) microglial activity in the subgenual anterior cingulate cortex 
(sgACC) and insula and confirmed significantly increased [18F]FEPPA uptake in 
depressed patients (N=12) compared to healthy controls (N=23). Using a seed-based ROI 
analysis of fMRI data, we found that patients show overall decreased connectivity 
between the sgACC and the insula. To test the relationship between inflammation and 
brain connectivity, we performed regressions which found functional (sgACC-insula) and 
structural (cingulum bundle) connectivity to be significant factors in explaining the 
microglial activity in the left sgACC. Our study suggests that neuroinflammation relates 
to network function in MDD.  
Keywords 
Major Depressive Disorder, Depression, Late-Life Depression, Neuroinflammation, 
[18F]FEPPA, Positron Emission Tomography (PET), Magnetic Resonance Imaging 
(MRI), Microglia, PET/MR, Neuroinflammation; Functional connectivity; Treatment-








Summary for Lay Audience 
Major depressive disorder is a brain illness which affects many people worldwide. 
The main symptoms are depressed mood and loss of pleasure, with additional symptoms 
such as lack of concentration and fatigue. Previous studies have shown that there are a 
variety of reasons why depression could occur, but the focus of the current thesis is the 
inflammation hypothesis. In the brain, when the inflammatory response is activated, 
microglia, the resident immune cells in the brain, will become activated. Microglia 
influence the body’s inflammatory response, and their activation can be measured through 
positron emission tomography (PET) imaging of a protein on their surface. It has been 
shown in the past that certain areas of the brain have greater microglial activity in 
depression.  
The functioning of different brain areas also plays a role in the development of 
depression. The simultaneous activation of areas such as the anterior cingulate cortex and 
the insula can be disrupted due to depression; this simultaneous activation represents an 
activation-related connectivity between the regions. Those two areas are involved in 
mood and self-examination. We can measure levels of activation of specific brain areas 
with magnetic resonance imaging (MRI). What we do not know is how disrupted brain 
connectivity is related to microglial activity in these areas. 
The first goal of this thesis was to measure brain inflammation through microglial 
activity, particularly in areas noted by other studies. The second goal was to measure 
brain connectivity between these areas in the brain. The third goal was to see if brain 
connectivity and microglial activity are related in any way. We expected increased 
inflammation and decreased brain activity in depressed individuals. We also expected that 
they would be related to one another. 
We found that, as we predicted, in these brain areas inflammation was increased 
and brain activity was decreased in depression. We next found that brain connectivity is 
related to inflammation. We believe that the continuous study of the neurological basis 
for depression will help physicians and pharmaceutical scientists develop new and more 
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1 Depression, Its Burden, and the Knowledge Gap 
 
This thesis contains research pertaining to the etiology of major depressive 
disorder (MDD), a highly debilitating mental illness. Mental illnesses negatively impact 
an individual’s mood, thoughts, or behaviour, leading to distress and impairment in daily 
activities. Depression is the most common of all mental illnesses and the leading cause of 
disability worldwide, having a lifetime prevalence of 20.6% in the US and 11.2% in 
Canada, and while manageable when treated, can have serious implications for quality of 
life when left unmanaged (1,2). There exists no one-size-fits-all cure for MDD; it is 
hypothesized that many different physiological pathways can contribute to its 
etiopathology. Modern treatment options rely on symptom management and include a 
combination of medication (selective serotonin reuptake inhibitors etc.) and 
psychotherapies. Despite the various options that are available, many patients develop a 
treatment-resistant state. In part, resistance may relate to our failure to address the 
mechanistic processes that underlie the illness. This thesis is an attempt to investigate one 
such pathway – neuroinflammation – in MDD. Several lines of clinical research on 
neurobiological pathways of depression, reviewed below, point toward depression being a 
systemic disorder with an inflammatory basis. The aim of this work is to fill the 
knowledge gap linking the notion of neuroinflammation to depressive symptoms and 
behaviours mediated by dysfunctional brain networks. 
 
1.1 Clinical Symptoms of Depression 
1.1.1  Major Depressive Disorder (MDD) 
MDD is a psychiatric illness which tends to run a remitting and relapsing course. 
It is common to experience multiple episodes; about 75% of individuals who have 
experienced a single episode of MDD will experience two or more at different points 




exponentially, while the time between each episode decreases (3,4). For an individual 
who has had at least one episode, the average number of MDD episodes is four, and each 
episode has an average length of twenty weeks (5,6). To be diagnosed with MDD, as 
defined by the Diagnostic and Statistical Manual of Mental Disorders 5 (DSM-5), one 
must have at least five of the following symptoms, with one of them being either 
depressed mood or loss of pleasure: depressed most of the day; diminished pleasure in 
activities all day or most of the day, every day; weight loss or weight gain without dieting 
or increase/decrease in appetite nearly every day; insomnia or hypersomnia almost every 
day; psychomotor agitation or retardation; fatigue; feelings of worthlessness or guilt; 
diminished ability to think; and recurrent thoughts of death or suicide ideation. The 
symptoms must cause distress or impairment in living and completing regular tasks, and 
the individual must not have experienced a manic episode. Each case of depression 
presents a varied combination of symptoms, and varied trajectories of outcomes, which 
has led to the notion that multiple distinct etiologies exist for this condition. For example, 
some with depressed mood may have pathophysiology associated with the medial 
prefrontal cortex, while others with predominant anhedonia and alterations in motivation 
may show a decrease in dopaminergic activity in the mesocortico-limbic pathway (7,8). 
These pathophysiological changes may also coexist in the same individual and may 
fluctuate over the illness course. 
1.1.2  Impact of MDD 
Depression affects over 168 million people around the globe, two thirds of whom 
are women, being one of the major contributors to reduced quality of life (9,10). In 
Canada, about 8% of adults will have had at least one MDD episode throughout their 
lives (11). Individuals with MDD are more likely to be hospitalized and are at increased 
risk of suicide. As well, they are two times more at risk of unemployment than those 
without MDD (12–14).  
Depression causes noteworthy economic and social burden; in Canada, mental 
health spending is projected to rise into the trillion dollar range by 2031 (15).  Depression 
causes patients to become less productive; those with depression will lose 5.6 hours of 




hours (16). This equates to 225 million lost workdays and $36.6 billion lost in salary per 
year in the US, and an additional cost of about $32.3 billion per year to the Canadian 
economy (4,17).  
 The negative effects are not limited to the social, as depression increases rates of 
morbidity and mortality. The physical impairments seen in depression are of a similar 
magnitude to those in chronic diseases such as diabetes and cancer (18). Depression is 
correlated with a subsequent cardiovascular episode, its associated mortality, as well as 
with increases in risk for cardiovascular disease, stroke, and hypertension; the risk of any 
cardiovascular event increases by 20% in individuals with four or more depressive 
symptoms as compared to those without (19–25). Individuals with depression are eleven 
times more likely to attempt suicide than healthy individuals, and about one in ten will 
attempt suicide (14,26,27). 
1.1.3  Late-Life Depression (LLD) 
While depression in the adult population has been somewhat better delineated, 
late-life depression (LLD) – depression occurring in an older population – is likely 
different in terms of etiopathogenesis and presentation. The specific criterion of age for 
LLD has not been widely agreed upon at this time, but the age of qualification for 
geriatric psychiatry-related services, i.e. greater than 65 years, has been considered to be 
most acceptable. The participants in the study were older (over the age of 50, with some 
over the age of 65), therefore the symptomatology specific to LLD should be considered.  
As is the case with MDD, individuals must have an episode lasting at least 2 weeks with 
one of the primary symptoms (anhedonia and depressed mood) and at least four of the 
secondary symptoms as previously described. The DSM-5 criteria seem to fail in 
diagnosis of late-life adults as complaints about failing bodily functions will be written 
off as expected for the age bracket (28). Help-seeking behaviour which comes in the form 
of persistent grievances with fatigue, pains, and headaches can be easily overlooked. As a 
result, depression in the elderly is underdiagnosed and undertreated. While there is 
growing interest in better defining LLD, there have simultaneously been attempts to 




the self-rated Geriatric Depression Scale (GDS) has been validated in capturing some of 
the typical somatic symptoms experienced by patients suffering from LLD. 
1.1.4  Impact of LLD 
More than 300,000 of the elderly in Canada are depressed, and this is associated 
with $5 billion in health care costs per year -- a number which ever-growing in today’s 
aging population (29). 1 in 10 of older adults are diagnosed with LLD at some point in 
their life (30). Older adults in the community with depression have a prevalence of 
11.2%, but institutionalized older adults have even higher rates (30). 12-45% of LLD 
patients in hospitals reported symptoms of depression, and 12.4% of those in care homes 
had major depression (31,32). Those in care homes tend to be placed there as a 
consequence of caregivers becoming overwhelmed with the increasing demand and 
mental load needed for elderly care.  
 LLD is associated with both non-suicide and suicide mortality in older adults 
(33,34). In a Statistics Canada study, it was found that 19% of the suicide victims in 
Canada were over the age of 60, and of those men made up the majority. LLD patients 
may be more likely to commit suicide through more violent and deadly means, with 26% 
of suicide victims over 60 using firearms compared to only 12% of those aged 15-39 (35). 
1.1.5  Late-Life Depression vs. Adult Depression 
LLD is symptomatically distinct from adult depression, with LLD patients, for 
example, having a pronounced fear of falling (36,37). The stressors specific to late-life -- 
forced retirement, chronic illness, cognitive decline, social isolation, caregiving, financial 
distress, loss of independence, and bereavement -- can create an environment which leads 
to the development of LLD (38). Views towards life and death itself will be unique to 
older individuals as compared to those who are younger (39). Those with greater harm 
avoidance, insecure attachment, low extraversion, neuroticism, low self-esteem, no sense 
of greater purpose, no social roles, and lower education will be at greater risk for 
developing LLD. As well, those of the female sex and with nutritional deficits, especially 




Unlike depression associated with adult age, LLD is oftentimes comorbid with all-
cause dementia (1.85, 95% CI 1.67-2.04, P<0.001), Alzheimer’s disease (1.65, 95% CI 
1.42-1.92, P<0.001), and vascular dementia (2.52, 95% CI 1.77-3.59, P<0.001) (41). 
Depression can be a signalling factor for dementia, and some claim that LLD is a risk 
factor for mild cognitive impairment and neurodegenerative diseases (causation has not 
been determined in this case). Comorbidities with other medical illnesses in LLD can 
affect scores on rating scales; elevated scores for eight items from the Hamilton Rating 
Scale for Depression (HAMD, Hamilton, 1960) have been observed in individuals over 
the age of 70, likely due to such somatic comorbidities (42). In addition, it seems that the 
pathways underlying depression in older populations may differ. For example, white 
matter hyperintensities have been revealed to play some role in the development of 
depression while their presence in younger adults is uncommon (43). Despite knowledge 
of dissimilar physical symptoms in adult and late-life depression, differences between the 
treatment of these two groups have not been distinguished and refined, an oversight 
which has left many older adults with insufficient resources to manage their symptoms. 
 
1.2  Treatment of Depression 
1.2.1 Treatment Options 
The treatment of depression can be divided into three broad categories: 
medication, psychotherapy, and alternative treatments. For the purposes of this thesis, we 
will be focusing on the former. Each type of treatment can be offered alone, but it is 
recommended to receive them in combination to gain maximum benefit. Medications, or 
antidepressants, are the most relied-upon treatment and come with a variety of options. 
Selective serotonin reuptake inhibitors (SSRIs) are the most prescribed of the 
antidepressants. They act by blocking the reuptake of serotonin and therefore increase 
serotonin signalling. Other types of antidepressants such as serotonin and norepinephrine 
reuptake inhibitors (SNRIs), 5-HT1A receptor antagonists, and dopamine reuptake 
blockers function similarly with the basic principle of regulating levels of 
neurotransmitters (namely serotonin, norepinephrine, and dopamine) in the brain. Most 




discovered many decades ago; no novel drug therapies have entered the market except for 
esketamine, a ketamine-derived glutamate receptor blocker which was FDA-approved in 
2019, and agomelatine, a melatonin receptor agonist approved for use in Europe in 2009 
and Australia in 2010. Interestingly, within the last decade the monoaminergic hypothesis 
of SSRIs has been questioned, and has even been speculated that their mechanism of 
actions may hinge upon anti-inflammatory pathways (44).  
Anti-inflammatory approaches have been considered for the treatment of 
depression as either add-ons or monotherapy (to be further discussed in Section 1.5.6) 
(45). Nonsteroidal anti-inflammatory drugs (NSAIDs), the most studied of the anti-
inflammatory drugs, have been found to have anti-depressant effects when compared to 
placebos and are inexpensive and easy to obtain (46). Their effectiveness relies upon the 
ability to reduce prostaglandins. One class of NSAIDs, selective cyclooxygenase-2 
(COX-2) inhibitors, are considered to have a more direct anti-inflammatory effect than 
other classes and therefore are more effective as treatments for depression (47–49). 
NSAIDs, however, may increase the risk of cardiovascular events (45,50). Cytokine-
inhibitors, which target cytokine synthesis, concentration, or related receptors, have a 
direct anti-depressant effect, although they may increase the risk of infection (46,51). 
Other groups of anti-inflammatory drugs which have shown anti-depressant effects 
include but are not limited to statins, corticosteroids, and poly-unsaturated fatty acids 
(PUFAs) (45).  
Despite the potential promise, it is not clear who should receive this treatment and 
the overall response rate is minimal as we are not able to stratify patients with 
neuroinflammation from those who do not have such inflammatory processes; 
furthermore, it is not clear how inflammation, which is generally a short-lived, 
constrained defence process, can lead to pervasive depression in those affected. This 
mechanistic understanding will help us identify the profile of inflammatory depression as 
well as aid in developing more empirically informed therapies. Moreover, the above 
treatments, inclusive of antidepressants, may not eliminate the risk of relapse, worsening 
of symptoms, or treatment-resistance.  
 




The ultimate aim regarding the above therapies is for the patient to achieve full 
recovery– the almost complete absence of burdensome symptoms. However, while they 
can be effective for many individuals, antidepressants can have little to no effect in some. 
Of those who receive “adequate” treatment for MDD, about 70% will respond to 
treatment, yet only 50% will fully recover; the remaining patients will not respond at all 
(52,53).  Other studies suggest that this value is even lower, with only 30% reaching the 
goal of full remission, and those previously classified as responsive experiencing residual 
symptoms such as fatigue and insomnia, contributing to increased risk of relapse (54–56).  
Those who do not sufficiently respond are referred to as having treatment-resistant 
depression (TRD). No consistent definition of this phenomenon exists, and clinicians may 
diagnose a patient if they do not respond to antidepressants whatsoever, or if they do not 
reach full remission after adequate dosing and course duration. Despite these differences, 
a concurrence between each definition is that to be diagnosed with TRD, one must fail to 
adequately respond to at least 2 courses of different antidepressants within an appropriate 
period of time. 
Of those who respond minimally, treatment resistance may arise from being 
prescribed a suboptimal dose, an unsuitable medication course, or discontinuing 
medication altogether. This is further complicated by comorbidities with illnesses such as 
anxiety and the heterogenous nature of depression itself, which make it difficult to 
develop universally effective treatments. Misdiagnosis due to these factors is not 
uncommon, and the inconsistency in TRD’s definition contributes to improper 
prescriptions of pharmacotherapies.  
The disregard for the disparity in symptomatology and disease progression 
between adult and late-life depression makes this issue even more pressing for the elderly. 
Atypical symptoms, somatization, cognitive decline, lack of education about drug 
therapies, and a lack of support from family can all contribute to cases of treatment-
resistant late-life depression (TRLLD) (57). The spectrum of possible depressive 
symptoms in older adults can range to bodily complaints such as stomach-aches and 
palpitations, present in about 20-80% of older patients but not commonly described in 
younger patients, leading to the belief that these individuals are experiencing side effects 




adults are similar to those below the age of 50, it has been shown that the same cannot 
always be said about the time course. In the first 6-12 weeks of treatment, over 80% of 
those with TRLLD will fail to respond sufficiently or will experience early relapse 
(58,59). 
  TRD is immeasurably onerous for those it affects. An inability to find relief from 
its physical and mental demands is taxing. It is easy to forget about the financial burden: 
those with TRD will be subject to increased medical costs compared to those who 
respond to treatment (60). They are more likely to be hospitalized and their hospital visits 
are six times the cost of a treatment-sensitive individual (61). It becomes apparent that 
establishing concrete means of diagnosing TRD and TRLLD is incredibly important.  
 
1.3  Explaining Depression – Inflammation as a Factor in its Development  
 
Social as well as biological factors such as genetics, aging, and physical diseases 
appear to have an effect on one’s mental health. The interplay between all of these factors 
and the degree of their severity may ultimately be what leads to depression, but the 
impact of each alone cannot be discounted (62). Predisposing factors may act on brain 
systems such as the frontolimbic networks and may bring about the vulnerability for 
depression, and promote chronicity and relapse (63). Etiological factors such as vascular 
changes, amyloid deposits, inflammation, and genetics may cause direct damage to 
reward, salience, and cognitive control networks, or may further increase the severity of 
the predisposing factors. Social stressors may lead to inflammation, oxidative stress, 
altered functional connectivity, or neurogenesis (64). These stressors may impact the 
brain in the same way as aging or disease-related processes. Social withdrawal behaviours 
associated with depression are linked with a desensitization of the hypothalamus-
pituitary-adrenal (HPA) axis due to dampening of a prolonged stress response (38). Stress 
may also lead to a direct neglect of health. All in all, the various ways through which 
depression may occur are diverse and numerous. The cause of depression cannot be 
explained by a single factor and requires a complete understanding of several interacting 
etiological factors. However, the mechanisms of each factor are still unclear and should 




works independently or synergistically and additively with other factors to produce 
depression. 
A widely considered mechanism for depression is neuroinflammation which is 
part of the body’s immune response -- a line of defense against infection and injury. The 
immune response can be classified into two categories: innate or acquired. The innate 
system is driven by white blood cells, while the acquired system consists of an 
immunological memory involving antigens and T and B lymphocytes. The question of 
whether the immune response involved in depression, a component of which being 
inflammation, is acquired has long been debated, but research has shown that there are 
increased T cell factors, implicated in both innate and acquired responses, in depressed 
individuals, suggesting that both systems may be at play (65,66). Despite having some 
answers to this broad and undeniably elemental question, it is only a small facet of the 
system at large and is representative of the larger dilemma seen in this field: there is a 
current lack of understanding of the complexity of the relationship between inflammation 
and MDD.  
 Complicating the matter further, inflammation can occur throughout the body and 
is present in a number of conditions, such as allergies, autoimmune diseases, and 
infections. This is inclusive of depression, which seems to be the main neuropsychiatric 
illness explained by brain tissue inflammation, but brain inflammation may play a role in 
the aetiologies of several other brain illnesses including schizophrenia, Parkinson’s, 
epilepsy, and Alzheimer’s. The focus of this thesis is on neuroinflammation as a theory 
explaining the development of MDD. The following is an overview on 
neuroinflammation-related findings for MDD, including relevant tools for its 
measurement and mechanisms of action.  
 
1.4 The Anterior Cingulate Cortex and Insula as Important Nodes of 
Functional Connectivity in Depression 
 
A variety of brain networks involved in processing of emotional information are 
thought to be relevant to the pathophysiology of depression. Two areas of the brain which 




displayed evidence of involvement in neuroinflammation (to be further discussed in 
Section 1.5.8) are the insula and the anterior cingulate cortex (ACC). The insula, an area 
with connectivity to depression-related regions, including the subgenual ACC (sgACC), 
which is involved in processing salient stimuli and regulating interoception (67,68), 
exhibits dysregulated functional connectivity (or temporal correlation with separate 
brain regions) in individuals with MDD (69–73). Such dysregulation has been associated 
with the development of a variety of cardinal features of MDD, including loss of pleasure 
(74–76). More precisely related to treatment of depression, its activity is altered as a 
result of depression treatment and can predict treatment outcomes. Antidepressants 
reduced insular activity (77,78) while regional cerebral blood flow in the insula was 
reduced with repetitive transcranial magnetic stimulation (rTMS), a popular treatment for 
TRD (79). Additionally, the right anterior insula was identified as a key factor in 
responsiveness to CBT or antidepressants (80). In a particularly insightful study using the 
insula as a seed region, the effective connectivity, or the influence one neural system 
exerts over another (81), of the insula with the dorsomedial prefrontal cortex (DMPFC) 
and from the pulvinar and visual cortex to the insula were shown to be diminished, which 
suggests a debilitated connection between the insula and higher processing as well as 
sensory regions in MDD (82).  
Marrying the concept of treatment response and effective connectivity using 
rTMS, Iwabuchi et al. (2019) demonstrated that pre-treatment fronto-insular effective 
connectivity predicted response to rTMS treatment at 1 month in those with TRD, while 
right anterior insula cerebral blood flow was negatively correlated with the same 
treatment outcome, further cementing the insula’s role in depression-involved brain 
networks (83). The above studies highlight the differential relationship the insula has with 
regions such as the DMPFC in MDD, a relationship which is modulated by treatment 
response, and how insula physiology can be improved with depression-targeted 
treatments. 
Similarly, the ACC and sgACC are dysregulated in MDD, but interestingly, 
dysregulation of the sgACC’s connectivity with the insula has been consistently reported 
in MDD (71,84–88). The sgACC’s connectivity can be improved with and can predict the 




is not limited to rTMS; the baseline functional connectivity between the sgACC and 
superior frontal/temporal gyrus, as well as between the sgACC and the middle temporal 
gyrus predicted electroconvulsive therapy (ECT) response (91). In 2018, Weigand et al. 
found that depressive symptom improvement was predicted by the functional connectivity 
between the sgACC and the DLPFC, solidifying the sgACC’s importance in depression 
symptomatology and outcomes (92). Of relevance to the topic of the current study, 
increased sgACC activity can predict treatment resistance (93), and symptom 
improvement with, for example, ketamine, can normalize its hyperactivity (94). Such 
findings have made the insula and the ACC attractive targets for depression studies but 
there is still much left unexplained, especially regarding their role in neuroinflammation. 
In the current study, we focus on inflammation present in the sgACC and insula, and how 
this relates to their connectivity in MDD. 
 
 
Figure 1.1. Axial view of the insula and sgACC. The right and left insula (yellow) are 
functionally connected to the left and right sgACC (red). We expect a weaker 
connectivity between the sgACC and insula in depressed individuals (associated with 







 1.5  Findings Concerning Inflammation and Depression 
1.5.1 Mechanisms of the Neuroinflammatory Response 
There exist many inter-related theories as to how inflammation increases 
depressive symptoms, but for the purposes of this overview we will focus on three: HPA 
axis-modulated neuroendocrine dysfunction, infection, and microglial activation. The first 
of these theories involves the stress hormone system, the HPA axis. In response to 
stressors, the HPA axis signals for the release of glucocorticoids by the adrenal glands, 
which act on organs throughout the body to regulate physiological processes and have a 
negative feedback effect at various levels of the system (95). In depressed individuals, 
this system can become dysregulated, demonstrating higher sensitivity to hormones, 
particularly adrenocorticotropic hormone (ACTH), and higher levels of glucocorticoids, 
which may be a result of disrupted negative feedback (96–100). Glucocorticoids are well 
known to have anti-inflammatory effects, notably through glucocorticoid receptor-
mediated suppression of pro-inflammatory transcription factors, leading to decreased 
levels of pro-inflammatory cytokines and chemokines (101–104). These 
immunosuppressive effects can also occur through interaction with proinflammatory 
signalling pathways and can induce destruction of immune cells such as T lymphocytes 
(105). Although the anti-inflammatory effects of glucocorticoids have been studied in 
depth, they can likewise have pro-inflammatory properties through, for example, 
interactions with pro-inflammatory cytokines, an effect which seems to be exacerbated by 
stress (106–109).  
MDD is more highly prevalent in individuals with inflammation-related disorders 
– including but not limited to arthritis, cardiovascular diseases, multiple sclerosis, and 
diabetes – and it is possible that chronic systemic inflammation as a result of illness may 
contribute to MDD pathophysiology (110). When an individual becomes sick, they will 
experience a set of symptoms very similar to those of depression: fatigue, loss of 
motivation, anhedonia, and loss of pleasure, among others. This is categorized as 
“sickness behaviour,” and while different from depression itself due to its short-lived 
presence (only as long as the illness lasts), such symptomatology suggests that individuals 




long-lasting inflammatory response which has continued beyond the illness duration 
(111,112). During an illness, proinflammatory cytokines are produced at the site of 
infection and can proliferate throughout the body, traveling to the brain to cause 
depression-like symptoms and depression disorders through means such as the neural 
pathway which can activate primary afferent nerves like the vagus nerve or the humoral 
pathway which involves the choroid plexus (113–117).  
An additional pathway exists in the brain through which systemic inflammation 
can exert its effects, and that is by activating microglia in the brain, thereby triggering a 
neuroinflammatory state. Due to the significant mounting evidence and new means of 
measuring microglia in vivo in humans, we are currently interested in this final theory. 
Microglia are involved in the neuroinflammatory response by acting as macrophages and 
can be measured as a proxy for inflammation. While there are multiple methods through 
which their activation can occur, a specific example of a mechanism describing the 
activation of microglia and how this results in negative outcomes involves the activation 
of indoleamine 2,3 dioxygenase (IDO), which breaks down tryptophan (TRP), a serotonin 
precursor, into kynurenine (KYN) (Figure 1) (111,118–120). Serotonin is well-known as 
an essential monoamine neurotransmitter involved in mood and cognition, and formation 
of KYN bypasses the pathway through which it is formed. This process results in 
decreased serotonin, which is similar to what individuals injected with interferon alpha 
(IFN-α), an inflammatory biomarker, who develop depression experience: decreased 
serotonin and increased KYN (121). KYN can also lead to the production of kynurenic 
acid in astrocytes and quinolinic acid in microglia (119). This has been implicated in 
causing oxidative stress, a process involving an increase in reactive oxygen species, 
leading to tissue damage (119,122). It has been reported that depressed suicide victims 
exhibit increased levels of quinolinic acid in the microglia of the ACC post-mortem 
(123). Those with chronic illnesses who are being treated with interferon alpha (IFN-α) 
manifest decreased TRP, increased KYN and KYN/TRP ratio, and increased depression 
scores (124). Healthy individuals, when faced with an inflammatory challenge, 
experience an activated KYN pathway, as well as increased IDO (125,126). Injection of 
quinolinic acid precursor 3-hydroxykyneurinine (3-HK) into mice leads to depression-like 




(126–129). While the KYN pathway is not the only one which is associated with 




Figure 1.2. Kynurenine pathway of microglial activation – one of many contributors 
to neuroinflammation. Stress leads to increased inflammation in the body and brain, 
thereby increasing pro-inflammatory cytokines and leading to the activation of 
indoleamine 2,3 dioxygenase (IDO) and kynurenine-3-monooxygenase (KMO). IDO 
breaks down tryptophan (TRP) into kynurenine (KYN) while KMO facilitates the 
production of 3-hydroxykyneurinine (3-HK), eventually leading to quinolinic acid 
(QUIN) in microglia and oxidative stress. Kynurenine aminotransferase (KAT) catalyses 
the conversion of KYN to kynurenic acid (KYNA) in astrocytes. 
1.5.2 Peripheral Inflammatory Markers 
Measurements of peripheral inflammatory biomarkers are a simple method of 
assessing and confirming inflammation in the body. Inflammatory biomarkers, including 
but not limited to cytokines and acute phase proteins, are released by the body during 
immune processes and are exhibited in dysregulated amounts in those with 






increases in proinflammatory cytokines like INF-α and interleukin-6 (IL-6) in depression 
(130). Other inflammatory markers which are elevated in depression include acute phase 
proteins, chemokines, adhesion molecules, and inflammatory mediators like 
prostaglandins. These elevated levels even occur in those without any other recorded 
illnesses and in post-mortem brain tissue samples (131). Peripheral blood markers 
interleukin-1β (IL-1β), IL-6, tumour necrosis factor (TNF), and C-reactive protein (CRP) 
are the most reliable biomarkers of inflammation in individuals with MDD, as noted by 
numerous meta-analyses (130). Further, biomarkers such as TNF have been associated 
with genes involved in depression when involved in the immune response (132). Chronic 
elevation of these cytokines may lead to the adverse symptomatology of depression, and 
an increase in symptom severity is correlated with an increase in peripheral blood 
cytokine concentrations (133,134), although not every person with depression will have 
elevated levels of proinflammatory cytokines (130,135,136). This can be attributed to the 
heterogenous nature of depression. All in all, increases in proinflammatory cytokines 
observed in depression are the most basic means through which inflammation has been 
linked to depression. 
Levels of certain inflammatory biomarkers can be modulated using 
antidepressants. In a meta-analysis containing 22 different studies pertaining to 
antidepressant effect in MDD, it was found that IL-1β and IL-6 and depressive symptoms 
were decreased in those who had undertaken antidepressant therapy, expressly SSRIs 
(137). Wang et al. (2019) demonstrated that this is also the case with TNF (138). These 
studies effectively proffer a relationship between inflammatory markers and the 
expression of depression – a relationship which can be managed in part with therapies 
specifically targeting depression.  
In addition to increased innate levels of proinflammatory cytokines, 
administration of these cytokines can induce depressive symptoms. Administration of 
innate human cytokines such as TNF-α can lead to psychosis, delirium, and agitation, 
while administration, both acutely and chronically, of cytokine inducer 
lipopolysaccharide (LPS) in healthy volunteers leads to an increase in symptoms of 
depression (111,133,134,139). Individuals with established medical conditions see similar 




as a result of medical conditions, but who themselves were not originally clinically 
depressed (140,141). 35.6% of individuals with asthma experienced symptoms of 
depression, and those who were depressed had higher levels of TNF-α (142), while 
illness-induced increases in IL-6 and nuclear factor kappa B, which is involved in the 
initiation of the inflammatory response, are correlated with depressive symptoms such as 
fatigue and insomnia (143,144). These “sickness behaviours,” as mentioned before, will 
disappear once the illness has ceased, but dysregulation of the inflammatory system may 
prolong their presence and this chronic exposure may contribute to MDD. In actuality, 
those with a medical illness are several times more likely to develop MDD (145). 
In related experiments, blocking cytokines such as TNF or other units of the 
inflammatory pathway, such as COX-2, has resulted in a reduction of depressive 
symptoms in individuals with medical conditions such as arthritis and cancer, and in 
individuals with MDD (46,146). From these findings it is apparent that inflammation at 
the systemic level is deeply intertwined with depression symptomatology which lends 
credibility to the infection theory of inflammation. Again, this is not the case in every 
individual with increased inflammatory markers or an inflammatory medical condition, 
which suggests that a specific faction of individuals is vulnerable to inflammation-derived 
depression. 
All this considered, the presence of inflammation alone is not enough to describe 
depression symptomatology. Inflammation is present in several neuropsychiatric illnesses 
including schizophrenia and obsessive-compulsive disorder, suggesting that it is possible 
inflammation has a multitude of neurological outcomes or a specific combination of 
biological factors must be present in order for the effects of inflammation to contribute to 
depression precisely.  
1.5.3 Blood Brain Barrier Permeability 
Until recently, it was not well understood how peripheral cytokines affected or 
were involved in the etiopathogenesis of depression at the level of the brain. As they exist 
in the plasma and are seemingly blocked from entry into brain parenchyma by the blood 
brain barrier (BBB), their connection to the brain was thought to be indirect (e.g., neural 




shown to be caused by chronic social stress in male mice. In the nucleus accumbens 
(Nac), an area associated with emotional regulation, claudin-5 (cldn5), a tight junction 
protein which acts as a cell adhesion molecule in the paracellular barrier between 
endothelial cells, is reduced and peripheral proinflammatory cytokines flow into the 
brain, leading to depression-like behaviours such as social avoidance, anhedonia, and 
helplessness. This process has been observed in post-mortem brain tissue samples of 
humans with MDD, effectively associating changes in the Nac endothelium with 
depression in humans (147,148). Other means through which peripheral cytokines may 
enter through the BBB include entrance of cytokines through leaky regions such as the 
circumventricular organ, passage of immune cells that generate cytokines into the brain, 
active transport, and increased inflammatory mediator signalling leading to production of 
inflammatory cytokines by microglia and subsequent BBB disruption (149–151). 
1.5.4. Cytokines and Brain Activity 
Since cytokines can enter the brain, it would be of interest to measure them in the 
brain along with their direct effects on brain activity. Unfortunately, levels of cytokines in 
the brain have been studied in most part using post-mortem samples (which are not fully 
generalizable), but the relationship between cytokines, brain activity, and brain 
connectivity has been a topic of interest with the development of more sophisticated 
neuroimaging technologies. The results of these studies demonstrate that there is an 
association between inflammation and dysregulation of both activity and connectivity of 
specific brain regions. Individuals treated with IFN-α have increased activation in the 
dorsal anterior cingulate cortex (dACC), increased arousal anxiety, and an increased 
alarm response (152). In an experiment, when subjected to a public speaking task subjects 
exhibited increased concentrations of oral IL-6 and soluble TNF receptor 2 (sTNF-R2), 
which was correlated with activation of the dACC in a social rejection task. In addition, 
activation of the amygdala was correlated with increased oral IL-6 expression in response 
to a social evaluation stressor, with participants who had the greatest IL-6 responses 
demonstrating the greatest connectivity in the fear network (amygdala, DMPFC).  
On the contrary, increased IL-6β has been associated with decreased activity in 




(153). Likewise, an increase in CRP was associated with a reduction in functional 
connectivity in a network including the ventral striatum, para-hippocampal 
gyrus/amygdala, orbitofrontal and insular cortices, and posterior cingulate cortex (154). 
These changes in connectivity were focused on the ventral medial prefrontal cortex 
(VMPFC), which mediates the relationship between CRP and anhedonia. While these 
results are the opposite of those mentioned previously, they all indicate dysfunction of the 
brain during inflammation. Increases in brain activation and connectivity in areas such as 
the ACC and amygdala being correlated with stress and inflammation create the 
foundation for our understanding of inflammation and its influence on the brain. While 
these studies do not include specific measures for depression or depressed subjects, and 
therefore cannot be directly related to its pathology, they reveal that inflammation has a 
very real effect on brain functionality. Of note, stress and inflammation are both 
predisposing factors for depression and their role in these studies allows for speculation 
on how depression may be involved (136).  
Other studies have found dysregulation of the brain associated with both 
inflammation and depression. Functional connectivity between the striatum and the 
VMPFC was correlated with increased peripheral IL-6, IL-1B, and IL-1 receptor 
antagonists in MDD (155). The striatum is further involved as increased cytokines reduce 
its activation with reward networks, and an injection of the typhoid vaccine, an 
inflammatory stimulator, can decrease connectivity between it and the subgenual ACC, a 
brain area associated with depression (Section 1.5). This connection is mediated by IL-6. 
Moreover, the changes seen in the brain are not limited to the functional; the physical 
properties of the brain have been shown to be altered in those with MDD. A thinner 
MPFC was found in MDD patients with a greater number of depressive episodes, and 
CRP level was inversely associated with right MPFC thickness (156). Hippocampal 
volume is negatively associated with higher levels of IL-6 and CRP in MDD, a 
potentially debilitating effect but not surprising as memory deficits are a recurring and 
common symptom of depression (157). What is most meaningful about these results is 
their direct linkage to depression; they tie together depression, inflammation, and brain 
measures in single studies. This confirmation that there is a relationship between all three, 




into their relatedness, as questions pertaining to how cytokines or other inflammatory 
markers correlate with specific brain changes, for example, remain unanswered.  
1.5.5 Late-Life Depression and Inflammation  
Studies investigating factors of inflammation in older depressed populations are 
unfortunately relatively rare despite available studies indicating inflammation as a factor 
in LLD and age itself furthering an inflammatory state (158). Increased expression of cell 
adhesion molecules in the DLPFC (associated with ischemia), of free 8-isoprostane, a 
marker for oxidative stress which can lead to chronic inflammation, and other 
proinflammatory biomarkers have been demonstrated in LLD (159–162). Decreases in 
inflammatory cytokine levels in older adults (mean age 60.3) after practicing meditation, 
as compared to a music group, highlight the presence of inflammation in and its 
relatedness to depression symptomatology in older adults (163). As previously 
mentioned, somatic comorbidities are often predisposing factors of LLD, so it is 
interesting that symptoms often complained about in old age such as frailty have been 
linked to chronic inflammation (164,165). More recently, a 2020 study by Sonsin-Diaz et 
al. found that compared to those who maintained low levels of CRP, older individuals 
(mean age 75.5) who have elevated levels of CRP throughout the majority of a 21 year 
period experienced depression symptoms of greater severity (166). This is further 
supported by Torre-Luque A. in 2019 and Kokkekler MJE et al. in 2020 who both found 
that inflammatory dysregulation is associated with increased depression severity in older 
adults (167,168). Overall, inflammation seems to play a critical role in the furtherance of 
depression in these individuals, and age may intrinsically lead to such outcomes, although 
it is not clear the extent to which inflammation affects older adults and if these effects are 
more severe.  
1.5.6 Antidepressant Effects of Anti-inflammatory Agents 
Another link between inflammation and depression is the effect that anti-
inflammatory agents can have on depressed individuals. A meta-analysis studied the 
effects of pro-inflammatory cytokine inhibitors on depressive symptoms, as compared to 




(169). In a study using infliximab, motor retardation, motivation, suicide ideation, and 
depressed mood were all significantly improved (170). Two separate meta-analyses found 
that in thousands of patients, anti-inflammatory drugs (including NSAIDs) improved 
depression symptomatology (171,172). It should be pointed out that these meta-analyses 
were performed in those with comorbid inflammatory conditions such as psoriasis, which 
are posited to have a separate mechanistic profile. Although these findings do suggest 
antidepressant effects of anti-inflammatory agents, the current evidence is not sufficient 
for progression to clinical use. It is unknown how anti-inflammatory agents affect specific 
depressive symptoms such as fatigue (45). Consideration of potential side effects, 
methodology for the identification of treatment-responsive patients, and comorbidities, a 
possible risk factor, will need to be completed. Most importantly, replicability of these 
findings will need to be achieved – a milestone which remains to be seen. Discrepancies 
in methodology have contributed to inconsistent research on the effects of anti-
inflammatory agents such as NSAIDs, and a consensus on research methodology is 
crucial for lending credibility to their use as antidepressants (173). Nonetheless, their use 
in research and their ability to have some effect on depression symptomatology create 
further evidence associating depression with inflammation. 
1.5.7 Treatment Resistance and Inflammation 
Little evidence exists at this point to link treatment resistance in depression with 
inflammation as measures of inflammation are not commonly assessed in TRD despite 
inflammation being an indicator of treatment response and it contributing to the potential 
existence of an inflammatory “subtype” of depression (174). Recent research has 
suggested that inflammatory dysregulation may be the difference between a treatment 
responder and a non-responder (175,176). This is substantiated by low monocyte 
chemoattractant protein 1 (MCP1), an inflammatory cytokine, being found to be a 
predictor of treatment resistance (177), along with increased peripheral IL-6 in majorly 
depressed patients who did not respond to amitriptyline treatment (178). Other peripheral 
cytokines, such as TNF, sTNF-R2, and IL-6 are elevated in those with 3 or more failed 




diverse proinflammatory biomarkers have been shown to be increased in those with TRD 
as compared to healthy controls (180,181).  
Specific expression combinations of inflammatory biomarkers and genes may be 
what contributes to this subtype. This may be why inflammatory biomarkers can have 
opposite effects in certain contexts (although this has yet to be elucidated). Interleukin-2 
(IL-2) detected before treatment has been associated with treatment resistance in the short 
term, but CRP, IL-6, MCP4 elevated post-treatment has been linked with poor long-term 
(3-12 months after hospital discharge) response to treatment (174). Furthermore, TRD 
patients with high inflammation (as indicated by elevated CRP levels) respond better to 
anti-inflammatory agents than those with low to average CRP (182). A follow-up study 
found these high inflammation patients displayed a unique lipid and glucose metabolism 
gene expression profile which is possibly an indicator of this inflammatory subtype of 
depression (183). If this subtype indeed exists, then treatment resistance in depression 
may be to a great degree influenced by inflammation or a distinct inflammation-related 
profile. Further research is needed to link inflammation and treatment resistance in 
depression. 
1.5.8 Microglia and Inflammation 
As previously mentioned, microglia play an important role in the inflammatory 
response as they mediate the cascade by acting as the macrophages of the brain. They 
release inflammatory mediators, and are involved in the overexpression of glutamate – 
leading to glutamate excitotoxicity – and in the production of quinolinic acid, a potent 
neurotoxin, from KYN (184). In chronically stressed mice, there is a decline in the 
number of microglia in the hippocampus, as well as decreased activation of said microglia 
(185). In individuals with multiple sclerosis, microglial activation is present and is 
associated with symptoms of depression (186). In MDD, microglial activity is linked with 
increases in levels of IL-6, IL-8, and TNF in the CSF and brain parenchyma, as well as 
with a reduction in astrocytes and oligodendrocytes (187,188). This reduction could be 
due to monocytes infiltrating the brain parenchyma as a result of increased permeability 
of the BBB (188). Suicidal individuals are known to have increased levels of monocytes 




white matter (189–191). This occurs in these patients regardless of if they fulfill DSM 
criteria. The above findings are reflective of cytokine data, wherein individuals with 
depressive symptoms as a result of other illnesses or inflammatory challenges experience 
microglial activation (133,192–194). 
Microglial activation and density can be imaged using positron emission 
tomography (PET) tracers, wherein the tracer binds to translocator protein (TSPO) on the 




TSPO total volume distribution (VT), or TSPO density, was significantly increased by 
26% in the prefrontal cortex, 32% in the ACC, and 33% in the insula in patients with a 
major depressive episode (195). In particular, the greater TSPO VT in the ACC correlated 
with greater depression severity and duration (196). The severity and duration of 
unmedicated MDD were strong predictors of TSPO VT, accounting for 50% of variance 
in TSPO VT in the prefrontal cortex, anterior cingulate cortex, and insula. Richards et al 
repeated the initial results while using [11C]PBR28 in major depressive episode (MDE) 
patients, finding that TSPO binding was significantly increased in unmedicated MDE 
patients, and could be decreased by psychotherapy (197,198). An additional [18F]FEPPA 
study found increased microglial activity in the hippocampus, while a study using 
[11C]CK11195 reported higher microglial activity in the ACC, the insula, and the 
prefrontal cortex in unmedicated MDD patients as compared to healthy controls 
(199,200). In LLD patients, increased uptake was correlated with levels of peripheral 
CRP (201). Overall, [18F]- FEPPA studies indicate increased microglial activity in MDD, 
and studies using other TSPO-PET tracers reflect these findings. 
On the contrary, Hannestad et al (2013) found that TSPO is not elevated in 
depression, although they used [11C]PBR28 as their radioligand (202).  Another study, 
also using [11C]PBR28 as a radioligand, was performed in 10 depressed individuals using 
injected LPS, compared to 10 healthy controls. They found that TSPO binding did not 
correlate with inflammation or mood even though TSPO levels did increase (203). In 
another study, IFNα was administered which led to a decrease in VT in the whole brain, 
but with correction this effect was eliminated. Mood changes were apparent in subjects 




could be attributable to differing study methodologies, as well as to differing TSPO tracer 
characteristics, or the potential suppression of microglia in specific conditions. Indeed, 
some studies have found decreased numbers of glial cells in the subgenual anterior 
cingulate cortex in depressed individuals compared to healthy controls (205–207), 
suggesting distinct roles for microglia. At this point in time there seems to be no clear 
consensus on how microglia should respond and how this may change in response to 
depression.  
Considering the above, it becomes apparent that the status of microglial activation 
in TRD is still unknown. Particularly of note, it is not clear if key frontolimbic regions 
such as the insula and ACC exhibit higher microglial activation, and how such activation, 
if present, relates to the connectivity between these two regions. In healthy individuals 
administered an inflammatory challenge, the resulting depressive symptoms are mediated 
by activity of the insula and sgACC (67,194). To further understand neuroinflammation 
in the sgACC and the insula, microglial activation in these areas can be measured. In the 
subsequent chapter, we examine this issue in human subjects. 
 
1.6 Imaging the Mechanisms of Depression  
1.6.1 In Vivo Measures of Inflammation 
Inflammation is frequently assessed through measurements of peripheral 
inflammatory biomarkers. This method is simple, cost-effective, and easy-to-complete, 
and as such has been well-established in literature. Biomarkers will be found at the site of 
inflammation, as well as circulating in plasma and serum, and can be measured from 
blood samples in addition to urine, saliva, and cerebrospinal fluid. A major drawback of 
this technique involves cases when the region of interest is the brain: one is unable to 
ascertain neuroinflammation, but rather a whole-body inflammatory state. Post-mortem 
brain tissue samples can be acquired to assess biomarker levels directly in the brain with a 
high degree of specificity, but these samples come from the endpoint of disease 





1.6.2 PET Imaging of Inflammation 
PET is the most highly sensitive imaging technique and is widely used in the 
research of neuropsychiatric disorders, movement disorders, and more. Microglial 
activation, and thus inflammation of the brain, can be quantified by detection of 
translocator proteins of 18 kDa (TSPO) which are expressed on the surface of 
mitochondrial membranes and are upregulated during the immune response. Many studies 
over the years have confirmed this upregulation during neuroinflammation (208) as in the 
brains of depressed individuals as described above.  
The most commonly used TSPO radioligand to study microglia to date has been 
[11C]PK11195 which poorly penetrates the blood brain barrier, has poor affinity for 
TSPO, high plasma protein binding, and a difficult process for synthesis. Second 
generation ligands – ligands developed from lessons learned from [11C]PK11195 – such 
as [18F]FEPPA, have a higher brain penetration rate as well as a high affinity for TSPO. 
[18F]-labelled radioligands have improved counting statistics and image quality 
compared to [11C], in addition to a longer half-life (20.39 minutes vs. 108.9 minutes) 
(209,210) which is better suited for clinical imaging. Other [18F]-labelled radioligands 
such as [18F]FEDAA1106 and [18F]PBR06 have many favourable properties but have 
issues such as being overly lipophilic or can confound quantification through the 
production of brain-penetrating metabolites (211,212). 
1.6.3  In Vivo Imaging of Brain Network Connections 
Magnetic Resonance Imaging (MRI) offers good spatial resolution, is non-
invasive, and has good spatial localization for both structural and functional imaging. 
Functional MRI (fMRI) applies radiofrequency pulses (RF) on a time-varying basis to 
measure variations in neural metabolism. The majority of fMRI imaging uses the blood-
oxygen-level-dependent (BOLD) MRI technique to detect changes in levels of 
deoxygenated hemoglobin, a measurement which acts as a proxy for neuronal activation. 
When an area of the brain is activated, this area will have an increased metabolic rate, and 
therefore receive a greater influx of cerebral blood flow to replenish depleted stores of 




deoxygenated hemoglobin as oxygen is delivered to the activated area. Initially, there will 
be a surge in deoxygenated hemoglobin as the affected area consumes the oxygen, but 
within a few seconds the deoxyhemoglobin will be overpowered by oxyhemoglobin as 
the body overcompensates for the amount of oxygen that is needed. This event is referred 
to as the hemodynamic response. Oxygenated hemoglobin is diamagnetic and 
indistinguishable from tissue, but deoxygenated hemoglobin is paramagnetic and creates 
gradients in the magnetic field which affect specific MRI signal parameters -- T2 and T2* 
relaxation times -- in the blood. The changes can be measured using BOLD fMRI while 
the subject is in a “resting state” (in the scanner with no particular thoughts) or in a task-
based situation with a specific set of rules to which the subject must adhere.  
Functional connectivity is the statistical probability of two or more regions of the 
brain being functionally related in time (213). These distant regions will show correlated 
activity in a resting state or in response to a task at the same moment. When regions are 
shown to be functionally connected consistently, they are considered to be components of 
a network. As a strength, this approach is relatively straightforward and without bias due 
to its lack of a priori assumptions. It is important to note that since this method is 
correlational, causation cannot be immediately assumed.  
1.6.4  In Vivo Imaging of Brain Macrostructure Connections  
 
Along with functional connectivity, depression symptomatology is linked with 
alterations in structural connectivity. White matter tracts associated with and connected to 
the ACC have been implicated in depression. A prominent white matter tract with 
projections from the cingulate gyrus towards the temporal lobe, forming a C shape around 
the corpus callosum, is the cingulum bundle. This tract has been linked with emotion, 
pain, and executive dysfunction (214,215) and, using diffusion tensor imaging (DTI), its 
integrity has been measured in depressed individuals, identifying decreases in fractional 
anisotropy and axial diffusivity, and increases in radial diffusivity (216–220). Such 
patterns of microstructure alterations have been associated with familial risk for 
depression (221), and reductions in fractional anisotropy have been correlated with 




of great interest for those studying MDD, it is currently unknown how neuroinflammation 
is related to its integrity in those with the condition. 
DTI is an MRI technique which measures the diffusion of water three-
dimensionally across the brain using diffusion weighted image (DWI). The diffusion 
tensor captured from DWI represents the three eigenvectors (which each correspond to an 
eigenvalue, a scaling factor) that characterize water diffusion direction and magnitude, 
along the three dimensions, which provides insight into white matter integrity. Diffusion 
measured in tissue will be anisotropic (vary depending on direction), and in white matter 
anisotropy can be caused by cellular membranes, myelination, and axon density. By 
modelling the diffusion tensor, diffusion tensor parameters that describe several aspects 
of water diffusion direction and magnitude can be calculated to characterize white matter 
macrostructure. The DTI parameters are 1) fractional anisotropy – the relative difference 
between the largest eigenvalue and the others, representing microstructural integrity, 2) 
mean diffusivity – the average of all three eigenvalues, representing membrane density, 3) 
axial diffusivity -- the value of the primary eigenvalue, representing diffusion along the 
main white matter tract, and 4) radial diffusivity -- the average of the 2nd and 3rd 
eigenvalues, representing demyelination. Statistical analyses of these parameters using 
ROIs, voxel-based analyses, or tract-based spatial statistics (TBSS) can be used to 
quantify brain macrostructure. ROI analyses can be biased and accurate parcellations of 
white matter regions are difficult to achieve. Voxel-based analyses are automated, 
spatially-specific, and avoid bias, but registration of individual brain images to a common 
space for statistical analysis requires complex algorithms and may not be accurate (223). 
TBSS is a recent method which eliminates issues with registration algorithms and the 
need to use spatial smoothing to reduce noise, therefore increasing statistical power (223). 
Here, TBSS was used to quantify connectivity in the cingulum bundle in relation to levels 
of inflammation measured with TSPO PET. However, DTI can be limited by challenges 
with tissue type differentiation (partial volume effects) as diffusion is averaged over a 
relatively large voxel, and by difficulty resolving crossing fibers – fibers from separate 
pathways -- as the tensor can only model a single major fiber direction (224). Thus, DTI 
can be difficult to interpret, and depending on the tissue type, brain region, and sample, 




useful in the study of neurodegenerative disorders, movement disorders, 




Figure 1.3. The cingulum bundle. The cingulum bundle (red) is a prominent white 
matter tract which forms a C-shape around the corpus callosum. It has been repeatedly 
associated with the pathophysiology of depression. We expect the neuroinflammation to 
reduce its white matter axonal integrity. 
 
1.7 Study Outline 
 
Individuals aged 50 years and older with treatment-resistant MDD were compared 
to healthy controls. After [18F]FEPPA injection, all individuals were scanned by a hybrid 
PET/MR system in order to assess microglial activity and functional/structural 
connectivity. PET images were used to obtain mean relative SUV data for the subgenual 
ACC and the insula. Functional images were used to assess functional connectivity with 
the ACC as a seed. DTI data was used to assess structural connectivity of the cingulum 




1.7.1 Study Objectives 
1. To assess [18F]FEPPA-traced microglial activation findings in treatment-resistant older 
MDD patients as compared to healthy controls. 
 
2. To investigate the relationship between microglial activity and functional connectivity 
between the sgACC and the insula. 
 
3. To investigate the relationship between microglial activity and white matter structural 
connectivity in the cingulum bundle. 
1.7.2 Study Hypotheses 
We hypothesized that subjects with MDD would demonstrate increased microglial 
activity in the insula and sgACC, and this aberration would be associated with alterations 
in functional connectivity between these two regions and with structural connectivity of 
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2 The Functional and Structural Consequences of 
Aberrant Microglial Activity in Major Depressive 
Disorder 
 
This chapter has been adapted from the following manuscript submitted to the Journal of 
Psychiatry and Neuroscience: The Functional and Structural Consequences of Aberrant 




 Major depressive disorder (MDD), characterised by recurrent cognitive and 
emotional dysfunction, is one of the most prevalent psychiatric disorders and a major 
contributor toward reduced quality of life (1). While the pathophysiology of MDD is not 
fully understood yet, various brain networks that facilitate cognitive and emotional 
information processing are thought to be relevant. Two critical brain regions for 
predicting therapeutic response and prognosis in MDD are the subgenual anterior 
cingulate cortex (sgACC) and the insula. Increased sgACC activity can predict resistance 
to treatment -- this hyperactivity normalizes with an improvement in symptoms (2,3) – 
and be altered by treatment itself (4–6). Similarly, the metabolic state of the insula, 
modifiable through MDD therapies, appears to be a critical determinant of response to 
various forms of treatment in MDD (7–9). Insula, through its extensive connectivity with 
other brain regions including sgACC, functions to assign salience to emotional and 
sensory stimuli and regulates interoception (10,11), the disruption of which has been 
associated with the emergence of several cardinal features of MDD (12–14).  
 Dysfunction of the immune system, and the resulting aberrant load of 
neuroinflammation, is increasingly considered to be an important pathway towards 
depressive illness, at least in a subgroup of patients with MDD. Aberrant 
neuroinflammation has major implications for treatment outcomes; conventional 




thus resulting in a treatment-resistant profile (15,16).  Microglia, which have an integral 
role in driving the neuroinflammatory response in the brain, have been shown to have 
increased activity in MDD (16–19), by using PET ligands (e.g. [
18
F]N-2-
(fluoroethoxyl)benzyl-N-(4phenoxypyridin-3-yl)acetamide or [18F]FEPPA) that bind to 
receptors expressed on the mitochondrial membrane of activated microglia.  Microglia 
may alter brain network connectivity through means such as synaptic pruning (20); this 
likely has downstream consequences on connectivity among brain regions.  Prior studies 
have linked peripheral and post-mortem markers of inflammation with alterations in 
resting-state functional connectivity in MDD (21,22). While excessive microglial activity 
has been demonstrated in vivo in MDD, we do not know if this has functional and 
structural consequences on brain networks relevant to the pathophysiology of depression.  
Subjective depressive consequences resulting from neuroinflammatory triggers in 
healthy volunteers are mediated by the neural activity in the insula and sgACC (10,23). 
The dysfunction of ACC, in particular its subgenual division, and its altered connectivity 
with the insula have been consistently reported in MDD (24–29). The insula, ACC as a 
whole, and the sgACC show increased microglial activity and density in MDD 
(16,18,19). In the current study, we focus on the microglial activity of insula and sgACC 
and the connectivity anchored on these nodes in MDD.  
Several white matter (WM) tracts have been implicated in depression.  The 
cingulum bundle is a WM tract associated with pain, emotion, and executive function 
(30,31) that carries a large fraction of projections from the ACC, towards regions that are 
critical in the pathophysiology of depression such as the hippocampus (32) and 
parahippocampal gyrus (33). In MDD, alterations in integrity of this tract have been 
reported and associated with axonal degeneration, familial risk, illness severity and 
persistence (34–40). In particular, patients with later-life depression are observed to have 
a higher load of WM lesions affecting the cingulum (41); deep-brain stimulation of the 
cingulum bundle is a promising treatment option for treatment-resistant MDD (42). We 
investigated the potential relationship between microglial activity and cingulum integrity 
in MDD.  
We hypothesized that in MDD increased [18F]FEPPA -measured microglial 




two nodes, and the severity of MDD. This current study investigated this relationship in 
four parts using a hybrid PET/MRI approach: (1) demonstrating aberrant microglial 
activity in sgACC and insula in MDD compared to healthy individuals, (2) relating 
microglial activity to the observed severity of depression, (3) evaluating the functional 
connectivity between the sgACC and the insula in MDD using functional MRI, (4) 
establishing the relationship between aberrant microglial activity and the structural and 
functional connectivity of the affected regions in MDD in comparison to the healthy 




Twelve depressed individuals aged 45 years and older referred to the Therapeutic 
Brain Stimulation clinic at the Parkwood Institute Mental Health Care Building (London, 
Ontario, Canada) were recruited between December 2017 and March 2019 for the study. 
PET/MRI data from 23 healthy volunteers recruited for an ongoing dementia imaging 
study were included as controls (Table 2.1). Patients were assessed by their treating 
psychiatrist per the Diagnosis and Statistical Manual of Mental Disorders, 5th Edition -
Structured Clinical Interview for DSM-5 to confirm their diagnosis (43). 
Symptomatology was reassessed at 6 to 12-month intervals. Up to two weeks before the 
scan, patients were administered the Montreal Cognitive Assessment (MoCA), the Beck 
Depression Inventory (BDI) test, Clinical Global Impression Severity scale (CGI-S), and 
the 17-item Hamilton Depression Rating Scale (HAM-D17) (44–47). The medication 
history, level of education, onset of depression, and treatment response were collected at 
study enrollment. 
All participants were free from confounding neurological or psychiatric disorders, 
or other conditions that could confound PET and MR imaging including known history of 
infection and autoimmune disorder. Given the known differences in TPSO binding 
affinity common to second-generation TSPO PET ligands, participants with low-affinity 
binding, which represents < 10% of the population, were excluded to reduce intersubject 




London Regional Genomics Centre at Robarts Research Institute and individual TSPO 
polymorphism status was included as a covariate in statistical analysis. This study was 
approved by the Western University Health Sciences Research Ethics Board and 
conducted in accordance with the Declaration of Helsinki ethical standards. All 
participants provided written informed consent. 
2.2.2 PET/MR Imaging 
Individuals were scanned once using a 3T Biograph mMR (Siemens Healthineers, 
Erlangen, Germany) utilising a 12-channel PET-compatible head coil in order to obtain 
both PET and MRI data in tandem. Each subject was injected with an intravenous bolus 
of [18F]FEPPA (185±5 MBq (5±0.1mCi)), synthesized at Lawson Health Research 
Institute following a reported method (49). Dynamic PET images were acquired for 90 
minutes in list mode, starting immediately following tracer injection. The 60 to 90 minute 
post-injection frames were reconstructed to six 5-minute frames using Siemens e7 tools 
and an iterative algorithm (ordered subset expectation maximization algorithm; 3 
iterations, 21 subsets, 2 mm full-width at half-maximum (FWHM) Gaussian filter, 2.5 
zoom factor, 344 × 344 × 127 matrix representing 2 × 2× 2 mm3 voxels), and corrected 
for decay, scatter, dead-time, and attenuation using an MR-based approach (50).  
A T1-weighted 3D magnetization-prepared rapid gradient echo (MPRAGE) 
sequence (slice thickness = 1mm, repetition time = 2000 ms, echo time = 2.98 ms, flip 
angle = 9 degrees, acquisition matrix = 256 × 256, and field of view = 256 mm) was used 
for generation of 1mm isotropic-voxel-tissue masks for PET attenuation and partial 
volume error correction, masking, co-registration of MRI with PET, and spatial 
normalization of images into Montreal Neurological Institute (MNI) space. fMRI images 
were acquired during rest with eyes opened in a 2 mm isotropic resolution covering the 
whole brain with 64 interleaved axial slices (slice thickness = 3 mm, repetition time = 
2500 ms, echo time = 30 ms, flip angle = 90 degrees, acquisition matrix = 80 mm × 80 
mm, and field of view = 240 mm). A total of 164 volumes were obtained; the first 6 were 
discarded to account for magnet stabilization. A 10-min diffusion-weighted imaging 
(DWI) scan was acquired using a single-shot EPI sequence with the following 




isotropic voxels. Two b0 images were acquired with opposite phase-encoding directions 
to correct for susceptibility-induced distortions in DWI.  
2.2.3 PET/MR Image Processing 
Preprocessing of PET images was done using the SPM12 toolbox 
(www.fil.ion.ucl.ac.uk) and in-house MATLAB (2018b; The MathWorks, Natick, MA) 
scripts. To compensate for motion, the PET time frames were aligned to the first frame 
and averaged to one image volume using the SPM realignment function and converted to 
standardized uptake value (SUV) images. T1-weighted images were segmented into grey 
matter, WM, and CSF using the segmentation tool in the computational anatomy toolbox 
(CAT12) (51). The grey matter segment was then smoothed using an 8 mm kernel to 
permit improved alignment of MRI to PET. A whole-brain mask generated from the 
cumulative sum of the gray matter, WM, and CSF segments were applied to the PET 
SUV images to remove extracerebral voxels. The SUV images were corrected for partial 
volume effects (PVE) using the Müller-Gartner method implemented in the PETPVE12 
toolbox in SPM (52). To ensure WM and CSF signal contamination were well-
compensated, the WM and CSF segments were eroded in MATLAB with morphological 
filtering and connected component analysis using a 2 × 2 voxel size. Point-spread 
function (PSF) for PVE correction was set at 5 mm isotropic to model the PSF of the 
PET/MRI scanner. The SUV images were spatially normalized to MNI space following 
the unified segmentation method (53), smoothed using a Gaussian filter with a FWHM of 
10 mm, and count-normalized by the mean SUV in the primary motor cortex to create 
relative SUV (rSUV) maps. Masks for the grey regional analyses were generated from the 
Automated Anatomical Labeling (AAL3; https://www.gin.cnrs.fr/en/tools/aal/) atlas. The 
masks were eroded by 2 voxels as described above to restrict inclusion of voxels outside 
of the ROI and minimize misalignment of ROI to individual PET images. Mean rSUV 
values were extracted from left and right sgACC and insula for statistical analysis. The 
sgACC has been distinctly reported to have higher microglial activity in voxelwise 
studies of MDD, while the insula has been reported to have higher microglial activity in 
ROI studies (16,18,19). In addition, we also explored other subregions of ACC (pregenual 




fMRI images were pre-processed using the default direct processing pipeline in 
CONN toolbox (Matlab2018b; www.nitrc.org/projects/conn, RRID:SCR_009550) and 
motion parameters were included as regressors. A seed-based analysis with the sgACC as 
a seed region was performed between patients and controls (excluding four control 
individuals due to frontal artifacts) including covariates (age and sex). Pearson’s r-to-z-
scores representing functional connectivity between the sgACC and the insula were 
extracted for statistical analysis. DWI data were preprocessed using an in-house pipeline 
to generate diffusion tensor imaging (DTI) scalar maps; fractional anisotropy (FA), mean 
diffusivity (MD), axial diffusivity (AD), and radial diffusivity (RD) maps (54). The DTI 
scalar maps were spatially normalized to MNI space using a three-step registration 
algorithm (consisting of rigid, affine, and deformable transformations to a standard MNI 
T1 1-mm template) in ANTs (55). Region-based analyses of DTI scalars were performed 
by calculating mean FA, MD, AD, and RD values in the cingulum bundle WM pathway 
using regional masks from the John Hopkins White Matter Atlas (56). While there are 
multiple metrics available from DTI, increased AD has been associated with axonal 
integrity (57,58) and increased extracellular water content; increased extracellular water 
content is a biomarker of neuroinflammation (59). Although metrics such as FA, MD, and 
RD may likewise be sensitive to water content changes, the specific activity of microglia 
may be more closely related to AD as they aid in engulfing axonal debris (60,61). We 
chose AD as the primary DTI index of interest for this analysis.  
2.2.4 Statistical Analysis 
Covariates of no interest included age, sex, and TSPO status.  Multiple linear 
regressions including covariates of no interest were performed to assess differences in 
regional microglial activity (rSUV) and in functional connectivity (z-scores) to determine 
the effect of diagnostic status. Given the 4 ROIs chosen a priori, a Bonferroni-corrected 
statistical threshold of 0.0125 was used as the threshold for significance.  A multiple 
linear regression per ROI was performed with non-linear locally estimated scatterplot 
smoothing (LOESS) to assess the relationship between [18F]FEPPA uptake and HAM-D 
scores, and between [18F]FEPPA uptake and DTI measures of the cingulum bundle, 




To test the effects of functional connectivity on microglial activity, first a single factor 
representing all functional connectivity variables (left sgACC to left insula; left sgACC to 
right insula; right sgACC to left insula; right sgACC to right insula; left sgACC to right 
sgACC; left insula to right insula) was derived using principal components analysis 
(PCA). Next, a non-linear regression predicting left sgACC microglial activity with the 
PCA-derived connectivity variable and covariates of no interest was run across the whole 
sample. The connectivity variable and age were included as non-linear (LOESS) 
predictors while the categorical variables of diagnostic status, sex, and TSPO status were 
linear. The same models (excluding diagnostic status as a predictor) were run on patients 
and controls separately. Non-linear regressions were used to relate functional connectivity 
with [18F]FEPPA uptake, as both increased (62) and decreased (63,64) connectivity has 
been reported in preclinical and clinical studies of inflammatory markers, indicating the 
likelihood of a U-shaped relationship between microglial activity and functional 
connectivity. Including age and the PCA-derived factor as non-linear in the model 
reduced the model error significantly compared to the linear model. The number of knots 
included in the non-linear model was selected based on the generalized cross-validation 
(GCV) method, which uses leave-one-out cross-validation to minimize the model’s 
prediction error, thus minimizing overfitting.  All statistical tests were run using SAS 






















We found a significant increase in [18F]FEPPA uptake in patients when compared 
to controls in the left sgACC (t=2.684; p=0.012) while all other regions except the right 
pregenual ACC showed higher [18F]FEPPA uptake than controls but did not survive 
correction (Figure 2.1). [18F]FEPPA uptake from the left and right insula were significant 
predictors of HAM-D scores in a linear model including non-linear age (left p=0.039; 
right p=0.037) (Figure 2.2). Z-scores representing functional connectivity between the 
sgACC and the insula revealed no significant reduction in pairwise connectivity (Figure 
2.3; right sgACC-right insula p=0.053; left sgACC-left insula p=0.474; left sgACC-right 
insula p=0.059; right sgACC-left insula p=0.209). 
 
 
Table 2.1. Participant Demographics. 
 
Variablea Depressed (n=12) Healthy (n=23) 
Sex 8 F, 4 M 11 F, 12 M 
Age (yr.) 54.9 ± 4.5 60.3 ± 8.5 
TSPO Statusb 8 HAB, 4 MAB 12 HAB, 11 MAB 
MoCAc 26.5 ± 2.1 N/A 
HAMD-17  18.9 ± 7.1 N/A 
Age of Onsetd (yr.) 30.4 ± 13.8 N/A 
 
a All means include ± SD. 
b HAB=high affinity binder, MAB=mixed affinity binder. 
c Missing data from 1 subject. 






Figure 2.1. Differences in mean relative standard uptake values (rSUV) per region of 
interest (ROI). ROIs included left and right sides of (A) the whole anterior cingulate 
cortex (ACC; in violet), (B) its pregenual (green), subgenual (red), and supracallosal 
(blue) subregions, as well as (C) the insula. (D). ROIs chosen a priori for hypothesis 
testing are highlighted in the red box. Linear regressions were run for each ROI 
(including covariates), finding significant differences between patients (N=12) and 






Figure 2.2. The relationship between mean relative standard uptake values (rSUV) 
from the insula and HAM-D scores. A linear regression including age as a non-linear 
factor (LOESS) and sex as covariates found that both (A) left insula [18F]FEPPA activity 
(represented by rSUV; p=0.039) and (B) right insula [18F]FEPPA activity (p=0.037) 








Figure 2.3. Differences in subgenual anterior cingulate cortex-insula functional 
connectivity. A linear regression including age and sex as covariates found that 
functional connectivity (represented by Pearson’s r-to-z scores) did not significantly 
differ between patients (N=12) and controls (N=19) but was borderline significant in the 
connection between the right subgenual anterior cingulate cortex (sgACC) and the right 
insula (p=0.053) and between the left sgACC and the right insula (p=0.059). sgACCL is 
left subgenual anterior cingulate cortex; ICL is insular cortex left; sgACCR is right 




Figure 2.4. The relationship between mean relative standard uptake values (rSUV) 
and functional connectivity. Non-linear regressions including a PCA-derived functional 
connectivity factor and age as non-linear factors (LOESS), and linear covariates of no 
interest were run in order to assess the impact of functional connectivity (represented by 
Pearson’s r-to-z scores) between the subgenual anterior cingulate cortex (sgACC) and 
insula on [18F]FEPPA activity (represented by rSUV). (A) All six pairwise connectivity 




principal factor. (B) When using the whole sample (N=31), increasing functional 
connectivity was associated with a sinusoidal-like change in [18F]FEPPA activity 
(p=0.044). (C) In patients (N=12), increasing functional connectivity was associated with 
first a decrease, then an increase in [18F]FEPPA activity (p=0.015) while (D) in controls 
(N=19) there was again a sinusoidal relationship between connectivity and activity 
(p=0.035). 
 
Figure 2.5. The relationship between microglial activity and structural connectivity. 
Linear regressions including age as a non-linear covariate, and sex, TSPO status, and 
diffusion tensor imaging metrics of white matter integrity as linear predictors were run in 
order to assess the impact of white matter integrity of the cingulum bundle on microglial 
activity in MDD patients (N=12). (A) Increasing axial diffusivity was associated with an 
increase in microglial activity (p=0.023) (B) Increasing fractional anisotropy was not 
significantly associated with microglial activity (p=0.843). (C) Increasing mean 




Increasing radial diffusivity was not significantly associated with microglial activity 
(p=0.173). 
We then tested if functional connectivity between the sgACC and the insula 
(derived from a single principal factor explaining most of the variance of six pairwise 
connectivity variables between bilateral sgACC and insula = (4
2
) = 6) is a significant 
factor explaining [18F]FEPPA uptake in the left sgACC, the region with higher uptake in 
MDD. This was first done across the whole sample, finding that functional connectivity 
was a significant non-linear predictor of microglial activity (p=0.044; Figure 2.4B). When 
investigating patients and controls separately, functional connectivity was a significant 
non-linear factor for both groups in explaining left sgACC [18F]FEPPA uptake (patients 
p=0.015; controls p=0.035). Interestingly, higher [18F]FEPPA uptake related to optimal 
(near-average) connectivity in the healthy subjects, while in MDD, both reduced and 
increased connectivity occurred with higher [18F]FEPPA uptake (Figure 2.4B & 2.4D). 
Finally, we assessed the relationship between microglial activity of the left sgACC 
and WM integrity of the cingulum bundle. We found that AD, a measure of unidirectional 
diffusion, from the left cingulum bundle significantly predicted microglial activity of the 
left sgACC in a linear model (p=0.023) (Figure 2.5A) but FA, MD, and RD did not 





In the current study, we demonstrated 3 key findings relevant to the 
neuroinflammation hypothesis of MDD: (1) a significantly increased microglial activity 
in the left sgACC occurs in patients being treated for MDD; (2) the higher the microglial 
activity in the insula, the less severe the HAMD scores; (3) left sgACC microglial activity 
influenced the functional connectivity between the sgACC and the insula and the axonal 
integrity of the cingulum bundle in MDD.   
Setiawan and colleagues (2015) previously found increases in microglial density 




groups have replicated these results using analogous [11C]-PBR28 (16,18). Here, we 
localized these previous findings to the sgACC as a specific site of increased [18F]FEPPA 
uptake. The findings of Su and colleagues (2016) using a voxel-wise search in LLD (19) 
corroborate our localisation to sgACC. 
We found that microglial activity from the left and right insula predict HAM-D 
scores, but this relationship is negative. Prior studies have reported an increase in severity 
of depression with increasing microglial activity (16), but individuals with increased 
neuroinflammation showed better treatment outcomes as well (65). Our sample consisted 
of patients receiving long-term treatment, wherein depression severity was low among 
those with higher microglial activity. It is possible that the inverse relationship we report 
is more reflective of the post-treatment improvement in outcome in a subset of patients 
inclined to have higher neuroinflammation, as reported by (65), or of neuroprotective 
microglial activity (66). The relationship between symptom severity and microglial 
activity may differ according to stage of treatment, phase of illness, or treatment-resistant 
profile. It is also possible that different measures of microglia (rSUV vs. VT) between 
studies may have affected results, although the extent of this effect is unclear. 
Levels of sgACC-insula functional connectivity were likewise dependent on 
diagnostic status, which has previously been elucidated (67). As hypothesized, we then 
found that functional connectivity between the sgACC and the insula is significantly 
associated with microglial activity from the left sgACC in both patients and controls. To 
our best knowledge this is the first study to use PET/MR to investigate the functional 
consequences on [18F]FEPPA uptake in MDD. A study investigating the network 
pathophysiology as it relates to neuroinflammation (also using PET/MR) in Alzheimer’s 
dementia found that those with increased radioligand binding have abnormal functional 
connectivity (68). Although this study was done in Alzheimer’s patients, later-life MDD 
and cognitive impairment are highly correlated (with depression being an early risk factor 
of dementia), and the current results highlight a possible neuroinflammatory basis for 
both conditions.  
We note that patients with MDD have a V-shaped relationship between microglial 




individuals showed an initial increase in microglial activity with increasing functional 
connectivity, reaching a peak, with a subsequent decrease. In patients, both an increase 
and decrease in functional connectivity was seen in conjunction with higher levels of 
microglial activity. On a speculative note, these observations may reflect 2 different states 
of the microglia – neurotoxic state, seen in patients, where higher levels relate to extremes 
of functional connectivity, and a neuroprotective or surveillance state, seen in healthy 
controls, where optimal functional connectivity requires sufficiently high microglial 
activity, maintaining neuronal communication (69). A dynamic pattern of microglial 
activation, particularly the early increase and later switch to decreased activity, have been 
identified in a previous study chronicling the transition from cognitively normal to mild 
cognitive impairment to Alzheimer’s disease (69). The speculation presented here needs 
further confirmation in a longitudinal hybrid PET/MR study using a larger cohort of 
MDD with age-matched and medication-naïve healthy adults. 
When relating WM macrostructural connectivity to microglial activity, we found 
that AD (diffusion in a direction parallel to the WM tract) of the cingulum bundle was 
significantly associated with microglial activity in the sgACC. Currently, there is no 
consensus on the findings of specific DTI metrics in MDD, and meta-analyses have 
posited that characteristic patterns may be restricted to subsets of the disease (30,36). An 
increase in AD with increasing microglial activity may denote alterations in WM 
microstructure (i.e., axonal integrity), and since AD is associated with neuroinflammation 
(59) and microglia in particular (60,61), it is then, perhaps, that neuroinflammation may 
negatively impact WM integrity of the cingulum bundle. This relationship may signal 
increased axonal injury, prompting microglia to clear up axonal debris, or chronic 
activation of microglia which may facilitate axonal degeneration. Furthermore, although 
FA, MD, and RD were not significantly associated with microglial activity, their general 
trends are reflective of age-related patterns of axonal degeneration (70,71). This may then 
indicate that microglia have a similar effect as age which lends added support to a shared 
mechanism between Alzheimer’s disease and depression.  
While the specifics of how microglia are able to influence brain connectivity are 




pruning. Remodeling of neuronal circuits is an important function of microglia along with 
their role in the immune response. Abnormalities in this remodeling function can have 
negative impacts upon synaptic plasticity as well as behaviour (20). The remodeling 
function is mediated by microglia-neuron crosstalk, a reciprocal communication which 
when dysregulated may be involved in depression (20). Manipulation of the C-X3-C 
Motif Chemokine Receptor 1 (CX3CR1) pathway, wherein microglia-neuron 
communication is prominent, can affect and induce depressive-like behaviour in mice 
(72–74). Reduced CX3CR1 signaling, and therefore reduced transmission between the 
two cell types, can affect the efficiency of synapses to transmit signals and may result in 
modified connectivity, although there are many microglia-neuron signalling pathways 
through which this can occur; this includes microglial decline and senescence (75,76). 
While microglia have numerous states of activation, activation specific to inflammation 
has been linked with altered synaptic current in hippocampal neurons, meaning there is 
some precedent to these findings (77,78).  
Our study has a number of strengths including the use of hybrid PET/MR that 
mitigates the interval-related confounds that can affect multimodal acquisitions 
(improved spatial and temporal co-registration), correcting for genetic variations in TSPO 
status, as well as the use of a second-generation TSPO ligand. But we were limited by the 
sample size (increasing risk for type II error for exploratory analyses), a lack of task-
encoded fMRI data to further validate the relevance of the observed functional 
dysconnectivity, and use of a MDD cohort which was not medication-naïve. Medications 
could have anti-inflammatory properties which could alter intrinsic brain activity and 
influence functional states. Nevertheless, we were sufficiently powered to detect the 
group differences as reported. Using previously reported effect sizes for the association 
between microglial activity and depression severity ( r=+0.63) (16) and assuming a power 
of 80%, with a type I error rate of 5% and a type II error rate of 20%, we estimated that a 
minimum of 12 patients would be sufficient to detect regional-level differences. 
Secondly, the use of SUV and reference regions as compared to other methods such as 
kinetic modelling and supervised cluster analysis further limits the strength of our 
findings and employing these methods in the future will be necessary for confirmation of 




TSPO imaging is a promising non-invasive tool for research of in vivo responses 
to inflammation; nevertheless, there are inherent limitations to its use. Microglial 
activation is described as pro-inflammatory or anti-inflammatory, but this idea is shifting 
due to emerging research on the ever-changing inflammatory state/morphology of glial 
cells in response to the environment. An increase in TSPO expression has been associated 
with both pro-inflammatory and anti-inflammatory states, and TSPO-specific 
radioligands are unable to distinguish the different states (80,81). This could be due to the 
states existing in a continuum rather than a binary. It may also be that these TSPO-
radioligands measure microglial density rather than microglial activation, and that they 
represent a combination of microglial as well as astrocytic signalling (82,83). This lack of 
specificity in inflammatory states may also be a challenge for other radioligands designed 
to image neuroinflammation by targeting other inflammatory processes besides TSPO, 
including emerging radioligands that specifically bind to microglia and not astrocytes 
(84). In addition, TSPO imaging is constrained by a rs6971 gene polymorphism, which 




In general, our study first highlights the central role that activated microglia may 
play in key brain circuits to influence the mechanistic processes (axonal integrity, 
functional connectivity) and behavioural phenotypes (symptom severity) relevant to 
depression. Secondly, our work reinforces the need for hybrid PET/MR as a translational 
neuroimaging tool. Linking mechanistic hypothesis at a receptor/cellular level observed 
using PET, to network-level dysfunctions observed using DTI/fMRI is a crucial step to 
generate a more systemic understanding of the pathophysiology of psychiatric disorders.  
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3.1 Summary  
 
Throughout the current thesis we have aimed to understand the relationship 
between FEPPA-measured microglial activity and both functional and white matter 
connectivity in MDD as this has not been previously elucidated. We have concluded that 
(1) microglial activity from the left sgACC is significantly increased in MDD, (2) insular 
microglial activity is negatively associated with depression severity, (3) functional 
connectivity between the sgACC and insula is decreased in MDD, (4) microglial activity 
from the left sgACC is non-linearly related to functional connectivity and (5) white 
matter connectivity is linearly associated with microglial activity. 
The diagnostic status-dependent differences in microglial activity and functional 
connectivity have been well-established in previous literature. The disparity in microglial 
activity between patients and controls reflects our current understanding of microglia as 
having an important role in depression symptomatology. The negative association 
between microglial activity and depression severity may be a post-treatment improvement 
in outcomes in those with higher neuroinflammation as our sample consisted of 
individuals receiving long-term treatment (1).   
The double peaks in microglial activity in relation to functional connectivity may 
be the result of two microglial phenotypes of activation (2): a neurotoxic state which 
occurs in patients at the lowest extreme of functional connectivity, and a neuroprotective 
state in healthy controls which requires high microglial activity at optimal functional 
connectivity to maintain microglia-to-neuron crosstalk.  
Increased AD of the cingulum bundle is associated with decreased microglial 
activity. When considering all DTI metrics (decreased FA and increased MD, AD, and 
RD with increasing microglial activity) together, it becomes apparent that the effect of 
microglial activity on white matter (or vice versa) is similar to age-related effects, 





3.2 Significance  
  
MDD is a heterogeneous condition which cannot be fully explained at the time of 
this thesis. This makes finding the most effective treatment difficult, especially in those 
with TRD; in some cases, the most effective treatment has yet to be recognized as a 
viable option. MDD diagnosis is further complicated by age, through which we see 
distinct differences in those with MDD and those with LLD. These distinct differences 
have not been widely studied to date, contributing toward a large gap in knowledge. It 
becomes imperative that a better-cultivated understanding of MDD is acquired for 
development of novel treatments which are suited for specific subsets of depression. 
Considering this, the results of the current study are significant. We have further studied 
the specifics of microglial activity in depression and related this with functional and 
structural connectivity. This is completely novel as no other groups, to the best of our 
knowledge, have related microglial activity with both functional and structural outcomes 
in MDD. What is especially important about this development is that we are able to better 
understand the interplay between different brain systems, something which has not been 
done extensively in depression. These separate systems function in tandem to produce 
what we know as clinical depression, and while we know a great deal about each one, 
with limitations in current research methods, the ways in which they work together are 
relatively unknown. 
Building on this further, current research has singled in on the ability of anti-
inflammatory agents to reduce severity of depression symptomatology. While at this 
moment anti-inflammatory agents and the phenomenon of neuroinflammation itself are 
nowhere near assiduously studied, their recent rise in research fascination has made our 
study apt for filling this gap in knowledge. It therefore becomes possible that anti-
inflammatory agents can be recognized as viable MDD adjuvant treatment options in the 
future. Understanding this relationship may lead to a breakthrough in the future of 
depression treatment – something which is sorely needed considering the current lack of 
novel options. 
Our results are reflective of previous studies of Alzheimer’s disease, further 




with late-life depression are at risk for dementia; since the microglial activity in our 
population reflects that of the decline into Alzheimer’s, it may be that microglia play a 
pivotal role in disease progression, and likewise in the concurrent development of 
Alzheimer’s. At this point this is speculation, but it illuminates a potential avenue for 
research into dementia prevention and treatment.   
MDD is the leading cause of disability today. It affects one’s productivity, one’s 
mood, and can lead one to taking their own life. It is not limited in who it affects, being 
the second leading cause of death among young Canadians (5). Such an illness cannot be 
taken lightly and any advancements in our understanding of it can aid in improving and 
saving lives. The importance of this cannot be understated; depression is isolating and 
deadly and with additional research we get closer to exceeding the current limitations of 
treatment. 
  
3.3 Limitations  
 
While the results shown are promising, as is the case with most studies they do not 
come without certain considerations. First and most glaringly, the sample size used in the 
current study is low. While our calculations of power do suggest that this sample size is 
enough to see significant differences, this is the absolute minimum. The choice 
in individuals within our sample is flawed as well. Those in the depressed cohort were not 
restricted based on their medications, and we cannot be sure what anti- or pro- 
inflammatory effects they may have. While the controls were age-matched (+/- 5 
years), in later life such an age disparity can have a significant impact. As previously 
mentioned in Chapter 1, there are physical and symptomological differences 
between MDD and LLD. This can completely change how the illness presents itself and 
how it arises.   
Secondly, the detection of microglial activity from TSPO in itself is 
challenging. TSPO expression is not limited to microglia, as it can be overexpressed 
in reactive astrocytes (6), withal in peripheral macrophages which may be able to cross 
the BBB to reach the brain (Dupont A.C. et al., 2017). It should be noted that levels of 




may pose problems as glutamate excitotoxicity is posited to be a significant factor 
in depression outcome (7). But this worry seems to not be of great consequence, as 
the contribution of TSPO from microglia may be about 7x greater than that of astrocytes, 
and the contribution of TSPO from these astrocytes has not yet been found to make a 
significant contribution toward the PET image (8). Nonetheless, the specificity of TSPO 
PET tracers in microglial binding should be considered in the future.   
Specificity of TSPO tracers to the type of microglial activation is another 
confounding factor. Microglia, previous to activation, are highly susceptible 
to environmental signals. Depending on the environment, when activated they can 
be described as either pro-inflammatory (M1) or anti-inflammatory (M2); the M2 state is 
thought to be less prevalent and can be activated by anti-inflammatory cytokines in 
addition to apoptotic cells and myelin debris, leading to tissue repair. The fact that it is 
possible for both of these responses to be active and that TSPO tracers seemingly do not 
distinguish between the two confounds interpretations of microglial activation. Moreover, 
the idea of concrete categories of microglial activity is shifting as it is theorized that the 
states exist in a continuum rather than a binary. It may also be that these TSPO-
radioligands measure microglial density rather than microglial activation (9).  
Thirdly, the choice in radiotracers and study design seems especially important, 
as there is no single convincing answer to the direction of microglial activity in MDD. 
Each study uses a different TSPO tracer, and studies are able to both replicate and 
completely deny previous findings depending on the tracer used. Considering that FEPPA 
has a greater specificity to TSPO than many other radioligands, it can be assumed that 
studies using FEPPA are more reliable and accurate. The effectiveness of TSPO tracers is 
further questioned when considering which ones may 
be impeded by MDD pathophysiology. A recent study by Turkheimer et al. found that in 
states of low-grade inflammation (in MDD and during inflammatory inducer injection in 
healthy individuals) uptake of TSPO tracers into CSF and brain parenchyma is decreased 
as compared to healthy controls due to a reduction in BBB permeability (10). It should be 
noted that the tracers used in this study were [11C]PK11195 and [11C]PRB28, not 
FEPPA. [11C]PK11195, while the first and most widely used TSPO radiotracer, has 




lipophilicity, and may not reflect FEPPA activity. [11C]PRB28 presents much of the same 
issues as [11C]PK11195 despite being an analogue to FEPPA.   
In conjunction with the issues related to choice of TSPO tracer, another 
consideration in interpretation of these results is that TSPO tracer uptake increases with 
age. A study done by Kumar and colleagues in healthy children and adults (age range of 
adults 20-49) found that adults overall have increased uptake of [11C]PK11195 while the 
distribution of TSPO tracer is not altered between groups (11). Given the difference in 
age between our control group and our patient group (with controls being about 5 years 
older and more definitively in a LLD categorization), it may be that the difference we see 
in microglial activity between patients and controls is diminished by the disparity in age. 
It is known that increased inflammation is associated with older age, but the exact origin 
of such inflammation is not fully understood. 
Finally, the choice of the reference region method of data normalization for the 
PET data is controversial. Reference regions must be picked carefully; they must have no 
significant differences in tracer uptake between patients and controls, and they must have 
relatively little TSPO tracer uptake. There exists no area of the brain with no tracer 
uptake, and as such there is no perfect reference region. A few reference regions have 
been validated in depression: the cerebellum is a common choice due to its large size, 
lending itself to greater stability. Reference regions are typically used as a simple 
alternative in the absence of arterial blood data. In the current study this data was not 
available, and we were unable to accurately model the tracer kinetics. Supervised cluster 
analysis methods are available to create supervised reference regions, but their 
development is time consuming.  
   
3.4 Future Directions  
 
While we have found a connection between functional connectivity and 
neuroinflammation-related molecular activity in depression, this is only the beginning of 
fully understanding this relationship. Due to the limitations above, the results must be 





In the future, it would be prudent to explore methods for absolute quantification of 
microglia that do not rely on reference region normalization. Absolute quantification of 
PET requires measurement of the input function – the time-dependent concentration of 
the PET tracer in blood plasma – to quantify the PET tracer concentration in tissue using 
tracer kinetic models. Although PET tracer kinetic modelling would allow for increased 
accuracy of PET measurements with fewer confounders, the need for serial arterial blood 
sampling makes this approach relatively invasive. Less invasive absolute quantification 
alternatives such as supervised cluster analysis would eliminate some of the issues 
associated with reference region-based normalization, as it uses a data-driven approach to 
identify the most suitable reference region.  
As well, it would enrich the current findings if serum inflammatory biomarkers 
were measured as to indicate levels of whole-body inflammation. Peripheral 
inflammatory biomarkers have been linked with dysfunction in connectivity in MDD 
(12), so bringing all of these factors together would solidify our conclusions. 
An interesting finding was the relationship between microglial activity and functional 
connectivity and how this reflected previous results found in Alzheimer’s disease.  
Although our subjects were older, they were not fully at risk for Alzheimer’s or 
other forms of dementia/cognitive impairment. This means it is possible that we are 
seeing a trend in microglial activity associated with age which may predict Alzheimer’s 
prognosis. In the future it would be intriguing to explore whether there are subtypes of 
microglial activation in the years leading up to being at risk for dementia, and if this is 
related to factors such as stress exposure. In order to do so, a larger sample size would be 
needed, as well as longitudinal data.  
Finally, we would be interested in relating the current findings to alternative 
imaging parameters, such as glutamate and glutathione, and in other brain regions, such 
as the striatum, in order to build a more cohesive story about depression as a whole.  
  
3.5 Concluding Remarks  
  
The results of this thesis suggest that inflammation is critical in depression and its 




and structural connectivity; thus, evanescent inflammation may have a longstanding 
impact of mood changes, as seen in post-viral depressive episodes. These findings are 
reminiscent of previous dementia and aging studies, giving insight into the interplay 
between separate systems and how their interactions contribute to clinical diagnostic 
status at large. Our work opens the possibility of using less expensive, more accessible, 
and less invasive DTI/fMRI metrics as a measure of the effect of reducing inflammation 
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